In a proposed pair of studies, the FDA will look at healthcare providers' and patients' responses to determine their ability to detect different…

Bayer’s $66 billion Monsanto takeover has plenty of critics. But thanks to an $8 billion R&D pledge, it has one key backer: U.S. President-elect Donald…

Astellas pulled the plug on a cell culture flu vaccine partnership with UMN Pharma after Japanese regulators stiff-armed its application for approval.

Allergan’s uterine fibroids prospect, Esmya, has racked up more data to support the FDA filing it expects to make later this year.

Several blockbusters are set for a nosedive this year as patent losses hit Novartis, Merck & Co., Bristol-Myers Squibb and other top pharmas.

Experts say the FDA's orphan drug system has been "hijacked" by drugmakers seeking protected profits on mass-market treatments.

The Supreme Court will take on a closely watched patent skirmish between Amgen and Novartis’ Sandoz that could determine timelines for future biosim launches.

Biogen has settled its Tecfidera patent fight with Forward Pharma for a whopping $1.25 billion in upfront cash, plus potential royalties, sending Forward'…

If there was any doubt that the oncology market is set to reach unprecedented heights, FiercePharma's top 15 list of cancer drugs in 2022 should eliminate…

Pharma